NAV

Miocamycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Miocamycin
DrugBank Accession Number
DB13287
Background

Miocamycin is a macrolide type antimicrobial 1. This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia 2. It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment 1.

Type
Biotech
Groups
Approved
Synonyms
  • Midecamycin acetate
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofBacterial sinusitis••••••••••••
Treatment ofBiliary tract infection bacterial••••••••••••
Treatment ofBronchitis bacterial••••••••••••
Treatment ofPharyngitis bacterial••••••••••••
Treatment ofPneumonia, bacterial••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Miocamycin.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Miocamycin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Miocamycin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Miocamycin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Miocamycin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
J01FA11 — Miocamycin
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
3T48CPS7U2
CAS number
55881-07-7

References

General References
  1. Holliday SM, Faulds D: Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1993 Oct;46(4):720-45. doi: 10.2165/00003495-199346040-00008. [Article]
  2. Kegg Japanese Pharmacopoeia [Link]
  3. AIFA Product Information: Macroral (miocamycin) for oral use [Link]
ChemSpider
16735908
RxNav
236200
ChEMBL
CHEMBL1091024
ZINC
ZINC000169677000
Wikipedia
Miocamycin

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Granule, for suspensionOral250 MG/5ML
Granule, for suspensionOral300 MG
Granule, for suspensionOral600 MG
Granule, for suspensionOral900 MG
Tablet, coatedOral300 MG
Tablet, coatedOral600 MG
TabletOral300 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at June 23, 2017 20:39 / Updated at October 27, 2020 21:12